Eli Lilly’s Foundayo obesity pill eases sleep apnea in late-stage trial, paving way for approval

Eli Lilly said Monday that its daily obesity pill Foundayo significantly reduced the severity of obstructive sleep apnea in patients with obesity, hitting the goal of a late-stage trial and setting up a regulatory filing before year-end.

The company plans to file by the end of the year for U.S. approval of the pill in adults with moderate-to-severe obstructive sleep apnea who also have obesity. Obstructive sleep apnea is the most common sleep-related breathing disorder, which frames the potential patient pool for a second indication on Foundayo.

The result matters because it moves Foundayo beyond weight loss alone. A sleep apnea label, if granted, would give Lilly a distinct, clinically defined use for an oral product, a format that sits apart from injectable obesity treatments.

Interpretation: a positive late-stage readout with a stated filing timeline shifts Foundayo's story from trial risk toward regulatory execution. The year-end target gives the market a concrete deadline to track rather than an open-ended pipeline promise.

The source does not provide the magnitude of the severity reduction, so the size of the effect remains the key unknown for assessing how competitive the label could be.